Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins (Q47201632)

11 January 2018

title

Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins (English)

1 reference

11 January 2018

author name string

G J Merli

1

1 reference

11 January 2018

G J Vanscoy

2

1 reference

11 January 2018

T L Rihn

3

1 reference

11 January 2018

J B Groce

4

1 reference

11 January 2018

W McCormick

5

1 reference

11 January 2018

publication date

1 May 2001

1 reference

11 January 2018

Journal of Thrombosis and Thrombolysis

published in

1 reference

11 January 2018

volume

11

1 reference

11 January 2018

issue

3

1 reference

11 January 2018

page(s)

247-259

1 reference

11 January 2018

https://scigraph.springernature.com/pub.10.1023/a:1011969005756

exact match

0 references

cites work

ASHP statement on the formulary system

1 reference

12 December 2020

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial

1 reference

12 December 2020

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

1 reference

12 December 2020

Pharmacokinetics of low molecular weight heparins in animal models.

1 reference

12 December 2020

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

Can we differentiate the low-molecular-weight heparins?

1 reference

12 December 2020

Therapeutic interchange of low-molecular-weight heparins

1 reference

12 December 2020

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis

1 reference

12 December 2020

Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis

1 reference

12 December 2020

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

ASHP national survey of pharmacy practice in acute care settings: prescribing and transcribing--1998. American Society of Health-System Pharmacists

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange.

1 reference

12 December 2020

Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators

1 reference

12 December 2020

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

12 December 2020

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

12 December 2020

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

1 reference

12 December 2020

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group

1 reference

12 December 2020

Therapeutic substitution and formulary systems. American College of Physicians

1 reference

12 December 2020

Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease

1 reference

12 December 2020

Low molecular weight heparins in the outpatient management of venous thromboembolism.

1 reference

12 December 2020

Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge

1 reference

12 December 2020

Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

12 December 2020

Outpatient treatment of pulmonary embolism with dalteparin

1 reference

12 December 2020

Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Optimizing anticoagulant therapy in the management of pulmonary embolism

1 reference

12 December 2020

Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis.

1 reference

12 December 2020

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

12 December 2020

Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

12 December 2020

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

12 December 2020

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

1 reference

12 December 2020

Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin

1 reference

12 December 2020

The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin

1 reference

12 December 2020

Guidelines for therapeutic interchange. American College of Clinical Pharmacy

1 reference

12 December 2020

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators

1 reference

12 December 2020

Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction

1 reference

12 December 2020

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

1 reference

12 December 2020

Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo

1 reference

12 December 2020

Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011969005756

1 reference

11 January 2018

Dimensions Publication ID

1019543984

0 references

1 reference

11 January 2018